Article Sidebar

PDF
Date Published: 10/03/2021
Abstract Views: 388
Views PDF: 316
DOI: https://doi.org/10.51298/vmj.v498i1.119
Issue
Vol. 498 No. 1 (2021)
Section
Các bài báo
How to Cite
Thị Kim Phượng, T., & Phong Thu, L. (2021). THE PROGNOSTIC ROLE OF SYSTEMIC IMMUNE-INFLAMMATION IN III-IV STAGE NON-SMALL CELL LUNG CANCER PATIENTS. Vietnam Medical Journal, 498(1). https://doi.org/10.51298/vmj.v498i1.119

THE PROGNOSTIC ROLE OF SYSTEMIC IMMUNE-INFLAMMATION IN III-IV STAGE NON-SMALL CELL LUNG CANCER PATIENTS

Trần Thị Kim Phượng1,, Lê Phong Thu1
1 Trường Đại học Y dược Thái Nguyên

Main Article Content

Abstract

Objective: To assess the prognostic role of pre-tretment systemic immune-inflammation index (SII) in advaced, metastsis non-small cell lung cancer patients treated with first-line chemotherapy. Methods: cross-sectional study design was conducted on 51 III-IV stage non-small cell lung cancer patients treated with first-line chemotherapy at Oncology Center of Thai Nguyen National Hospital from 01/01/2017 to 31/12/2018. SII index was calculated using formula: platlet count x neutrophil/lymphcyte count. The oftimal cut-off value was calculated by ROC curve. The median overall survival time (OS) were estimated using Kaplan-Meier method. A Log-rank test and Cox-regression model were carried out for univariate and multivariate analyses. Results: 22 patients had high SII (≥1.409) and 29 patients had low SII (<1.409). The median OS time was 23,7 months in low SII group and 13,1 months in high SII group (p<0,05). At multivariate analysis, pre-treatment SII and ECOG-PS were independent prognostic factors for worst OS. Conclusions: Pre-treament SII is independent prognostic factor for advaced non-small cell lung cancer patients treated with frst-line chemotherapy.

Article Details

Keywords

systemic immune-inflammation, non-mall cell lung cancer, chemotherapy, prognostic factor

References

1. Berardi, R., Santoni, M., Rinaldi, S., et al., "Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer", Ann Transl Med, 2019, 7(20), p. 572.
2. Cannon, N. A., Meyer, J., Iyengar, P., et al., "Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer", J Thorac Oncol, 2015, 10(2), pp. 280-5.
3. Guo, D., Zhang, J., Jing, W., et al., "Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer", Future Oncol, 2018, 14(25), pp. 2643-2650.
4. NSCLC Meta-analysis Collaborative Group, "Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data", Lancet, 2014,. 383(9928), pp. 1561-71.
5. Schernberg, A., Mezquita, L., Boros, A., et al., "Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer", PLoS One, 2018, 13(10), p. e0204490.
6. Tong, Y. S., Tan, J., Zhou, X. L., et al.(2017), "Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer", J Transl Med, 2017, 15(1), p. 221.
7. Wang, Y., Li, Y., Chen, P., et al.(2019), "Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis", Ann Transl Med, 2019, 7(18), p. 433.